Suppr超能文献

[间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌的诊断]

[Diagnosis for ALK positive non-small cell lung cancer].

作者信息

Feng Qin, Yang Xin, Lin Dongmei

机构信息

Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China.

出版信息

Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):61-8. doi: 10.3779/j.issn.1009-3419.2015.02.02.

Abstract

The anaplastic lymphoma kinase (ALK) gene rearrangement is a driver gene of non-small cell lung cancer (NSCLC). Positive expression of ALK gene rearrangement has been considered a molecular subtype of NSCLC, that there are special pathological characteristics and clinical prognosis. Furthermore, the tyrosine kinase inhibitor has demonstrated high effective in treating ALK positive NSCLC patients. Thus making molecular diagnostic testing for ALK expression is an important step in the process of pathological diagnosis. Currently, many detecting ALK expression assays are available or in development, clinical pathologists focus on how to choose the best method for routine diagnosis of lung cancer. There are many domestic and international authoritative guidelines recommend ALK detecting assays, technological process and relative standard. In the current review, we summarize the diagnostic tests available and the special sample types that could be used to identify patients with ALK-positive NSCLC.

摘要

间变性淋巴瘤激酶(ALK)基因重排是非小细胞肺癌(NSCLC)的驱动基因。ALK基因重排的阳性表达被认为是NSCLC的一种分子亚型,具有特殊的病理特征和临床预后。此外,酪氨酸激酶抑制剂已证明对治疗ALK阳性NSCLC患者具有高效性。因此,进行ALK表达的分子诊断检测是病理诊断过程中的重要一步。目前,有许多检测ALK表达的方法可供使用或正在研发中,临床病理学家关注的是如何选择最佳方法用于肺癌的常规诊断。有许多国内外权威指南推荐了ALK检测方法、技术流程及相关标准。在本综述中,我们总结了现有的诊断检测方法以及可用于识别ALK阳性NSCLC患者的特殊样本类型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ec7/5999849/6dee2a96a151/zgfazz-18-2-61-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验